Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors

Journal of Neuro-Oncology

Volumn 49, Issue 3, 2000, Pages 197-203

  Schiebe, M ^a   Ohneseit, P ^a   Hoffmann, W ^a   Meyermann, R ^a,b   Rodemann, H P ^a   Bamberg, M ^a  

^a Academic Hospital   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Gene amplification; Glioblastoma multiforme; Oncogene mdm2; p53 mutations; Prognostic value; Tumorigenesis

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

AGE; ARTICLE; CARCINOGENESIS; CODON; GENE AMPLIFICATION; GENE INACTIVATION; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POINT MUTATION; PROGNOSIS; SURVIVAL TIME; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ADULT; BRAIN NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENES, P53; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SURVIVAL ANALYSIS;

EID: 0034488325     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006410702284     Document Type: Article

References (29)

1. Radiation therapy of malignant gliomas
2. Frequency of tumor suppressor gene mutations in glioblastoma multiforme and its clinical value
3. p53 stimulates transcription from the human transforming growth factor alpha promotor: A potential growth-stimulatory role for p53
4. Loss of heterozygosity on chromosome 10 is more extensive in primary than in secondary glioblastomas
5. Molecular pathways in the formation of gliomas
6. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas
7. Astrocytes derived from p53-deficient mice provides a multistep in vitro model for development of malignant gliomas
8. Biology and treatment of malignant glioma
9. Dynamics of genetic alterations associated with glioma recurrence
10. Amplification at 12q13-14 in human malignant gliomas is frequently accompanied by loss of heterozygosity at loci proximal and distal to the amplification site
11. Amplification and overexpression of mdm2 in primary glioblastomas
12. Prognostic factors in astrocytomas: Relationship of p53, MDM2, BCL 2 and PCNA immunohistochemical expression to tumor grade and overall patient survival
13. Prognostic factors in malignant glioma: Influence of the overexpression of oncogene and tumor-suppressor-gene products on survival
14. mdm2 and p53 expression in gliomas: A multivariate survival analysis including proliferation markers and epidermal growth factor receptor
15. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or BCL-2 genes
16. The new WHO classification of brain tumors
17. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies
18. Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification
19. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification
20. Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors
21. A comparative study of epidermal growth factor receptor (EGFR) and MDM2 gene amplification and protein immunoreactivity in human glioblastomas
22. Regulation of transcription functions of the p53 tumor suppressor by the mdm2 oncogene
23. MDM2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein
24. Gene amplification as a prognostic factor in primary brain tumors
25. Prognostische wertigkeit genetischer marker (MDM2, 9p, 10q, 11p15, p53) in malignen gliomen
26. Phenotype vs genotype in the evolution of astrocytic brain tumors
27. The challenge of p53 as prognostic and predictive factor in gliomas
28. Gene amplification as a prognostic factor in primary and secondary high grade malignant gliomas